Peter I Terness

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi The T-cell suppressive effect of bufadienolides: structural requirements for their immunoregulatory activity
    P Terness
    Institute of Immunology, Department of Transplantation Immunology, INF 305, University of Heidelberg, 69120 Heidelberg, Germany
    Int Immunopharmacol 1:119-34. 2001
  2. ncbi Immunosuppressive anti-immunoglobulin autoantibodies: specificity, gene structure and function in health and disease
    Peter I Terness
    Institute of Immunology, University of Heidelberg, Germany
    Cell Mol Biol (Noisy-le-grand) 48:271-8. 2002
  3. pmc Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites
    Peter Terness
    Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, 69120 Heidelberg, Germany
    J Exp Med 196:447-57. 2002
  4. ncbi Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo
    Thomas M Bauer
    Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, 69120 Heidelberg, Germany
    Transpl Int 18:95-100. 2005
  5. doi Mitomycin C-treated antigen-presenting cells as a tool for control of allograft rejection and autoimmunity: from bench to bedside
    Peter Terness
    Institute of Immunology, University of Heidelberg, Department of Transplantation Immunology, Heidelberg, Germany
    Hum Immunol 70:506-12. 2009
  6. pmc Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases
    Peter Terness
    Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, Im Neuenheimer Feld 305, D 69120 Heidelberg, Germany
    Proc Natl Acad Sci U S A 105:18442-7. 2008
  7. doi Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: promises and difficulties
    Sandra Ehser
    Institute of Immunology, University of Heidelberg, Heidelberg, Germany
    Hum Immunol 69:165-73. 2008
  8. ncbi Inhibition of heart allograft rejection with mitomycin C-treated donor dendritic cells
    Lucian P Jiga
    Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany
    Transplantation 83:347-50. 2007
  9. ncbi Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients
    Gerhard Opelz
    Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany
    Transplantation 81:1227-33. 2006
  10. ncbi The immunoregulatory role of IDO-producing human dendritic cells revisited
    Peter Terness
    Institute of Immunology, Department of Transplantation Immunology, INF 305, University of Heidelberg, 69120 Heidelberg, Germany
    Trends Immunol 27:68-73. 2006

Collaborators

Detail Information

Publications20

  1. ncbi The T-cell suppressive effect of bufadienolides: structural requirements for their immunoregulatory activity
    P Terness
    Institute of Immunology, Department of Transplantation Immunology, INF 305, University of Heidelberg, 69120 Heidelberg, Germany
    Int Immunopharmacol 1:119-34. 2001
    ..A similar bufadienolide occurs naturally in mammals. We speculate that bufadienolides represent an important bioregulatory link between the cardiovascular, nervous and immune systems...
  2. ncbi Immunosuppressive anti-immunoglobulin autoantibodies: specificity, gene structure and function in health and disease
    Peter I Terness
    Institute of Immunology, University of Heidelberg, Germany
    Cell Mol Biol (Noisy-le-grand) 48:271-8. 2002
    ..There is substantial evidence indicating that anti-Ig auto-Abs are important immunoregulatory molecules...
  3. pmc Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites
    Peter Terness
    Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, 69120 Heidelberg, Germany
    J Exp Med 196:447-57. 2002
    ....
  4. ncbi Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo
    Thomas M Bauer
    Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, 69120 Heidelberg, Germany
    Transpl Int 18:95-100. 2005
    ..The metabolites induced a significant prolongation (P = 0.0018) of graft survival. We conclude that IDO-induced tryptophan metabolites suppress the T-cell response and prolong allograft survival in rats...
  5. doi Mitomycin C-treated antigen-presenting cells as a tool for control of allograft rejection and autoimmunity: from bench to bedside
    Peter Terness
    Institute of Immunology, University of Heidelberg, Department of Transplantation Immunology, Heidelberg, Germany
    Hum Immunol 70:506-12. 2009
    ..Although many questions remain, MMC-treated cells are a promising clinical tool for controlling allograft rejection and deleterious immune responses in autoimmune diseases...
  6. pmc Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases
    Peter Terness
    Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, Im Neuenheimer Feld 305, D 69120 Heidelberg, Germany
    Proc Natl Acad Sci U S A 105:18442-7. 2008
    ....
  7. doi Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: promises and difficulties
    Sandra Ehser
    Institute of Immunology, University of Heidelberg, Heidelberg, Germany
    Hum Immunol 69:165-73. 2008
    ..Based on lessons learned from the use of DCs as tools in clinical vaccine trials in cancer, we discuss the unknown aspects and risks of DC therapy in transplantation...
  8. ncbi Inhibition of heart allograft rejection with mitomycin C-treated donor dendritic cells
    Lucian P Jiga
    Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany
    Transplantation 83:347-50. 2007
    ..We conclude that allogeneic MMC-DCs specifically inhibit the T-cell response in vivo and that downregulation of CD80, CD86, and ICAM-1 is a potential mechanism of this effect...
  9. ncbi Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients
    Gerhard Opelz
    Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany
    Transplantation 81:1227-33. 2006
    ..It is widely assumed that the graft-enhancing properties of antilymphocyte induction agents and their lymphoma-inducing potential are intimately related...
  10. ncbi The immunoregulatory role of IDO-producing human dendritic cells revisited
    Peter Terness
    Institute of Immunology, Department of Transplantation Immunology, INF 305, University of Heidelberg, 69120 Heidelberg, Germany
    Trends Immunol 27:68-73. 2006
    ..Here, we critically examine the arguments for and against a function of IDO-expressing human dendritic cells (DCs) and conclude that proof for an immunoregulatory role in vivo is still lacking...
  11. ncbi Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO?
    Peter Terness
    Institute of Immunology, University of Heidelberg, INF 305, 69120 Heidelberg, Germany
    Blood 105:2480-6. 2005
    ..Our findings show that nonadherent CD123+/CCR6+ human DCs do not constitutively express IDO, and, even if they express the enzyme after IFN-gamma treatment, they possess only limited T-cell regulatory function...
  12. ncbi Generation of tolerogenic dendritic cells by treatment with mitomycin C: inhibition of allogeneic T-cell response is mediated by downregulation of ICAM-1, CD80, and CD86
    Lucian P Jiga
    Department of Transplantation Immunology, Heidelberg, Germany
    Transplantation 77:1761-4. 2004
    ..In this article, the authors study the effect of mitomycin C (MMC)-treated DC on rat T cells and delineate the mechanism of their conversion into tolerogenic cells...
  13. pmc Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma
    Michael Hundemer
    Department of Internal Medicine V, University of Heidelberg, Germany
    Exp Hematol 34:486-96. 2006
    ..The aim of this study was identification of human leukocyte antigen (HLA)-A2-restricted T-cell epitopes within the HM1.24 antigen as target for multiple myeloma (MM)-directed specific peptide-based immunotherapy...
  14. ncbi Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives
    Dinara Daniel
    Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany
    Int Immunopharmacol 3:1791-801. 2003
    ..The description of compounds without cardiac activity but with tumor-specific cytotoxicity suggests the potential of using them in cancer therapy...
  15. ncbi Comparison of six methods for the assessment of ischemia-reperfusion injury in skeletal muscle following composite tissue allotransplantation
    Steffen P Baumeister
    Department of Hand, Plastic, and Reconstructive Surgery, Burn Center, BG Trauma Center, Ludwigshafen, University of Heidelberg, Germany
    J Reconstr Microsurg 20:253-9. 2004
    ..These findings help further researchers in their selection of reliable outcome parameters to measure I/R injury in skeletal muscle...
  16. pmc Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma
    Sebastian Belle
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Eur J Haematol 81:26-35. 2008
    ..The aim of this study is the identification of HLA-A2 restricted T-cell epitopes in the conserved region of the immunoglobulin-G-heavy-chain (IgGH) that can be used for immunotherapy in multiple myeloma (MM) patients...
  17. ncbi Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells
    Peter Terness
    Institute of Immunology, University of Heidelberg, Heidelberg, Germany
    Am J Reprod Immunol 58:238-54. 2007
    ..Is the concept of maternal tolerance preventing rejection of the semi-allogeneic 'fetal allograft' still valid?..
  18. ncbi Ex vivo perfusion with mitomycin C containing solution prolongs heart graft survival in rats
    Daohu Wang
    Institute for Immunology, Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany
    Transplantation 82:1537-40. 2006
    ..Our findings indicate that the targeted perfusion of donor hearts with MMC-containing solution protects the graft from rejection...
  19. ncbi A simplified technique for heart transplantation in rats: abdominal vessel branch-sparing and modified venotomy
    Daohu Wang
    Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, 69120 Heidelberg, Germany
    Microsurgery 26:470-2. 2006
    ....
  20. doi Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24
    Olaf Christensen
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    J Immunother 32:613-21. 2009
    ..The current data demonstrate that Melan-A analog specific T-cells crossreact with HM1.24(aa22-30). They might be a tool for the future use in immunotherapy against MM...